

OPEN

Effects of a 12-week resistance and aerobic exercise program on muscular strength and quality of life in breast cancer survivors: Study protocol for the EFICAN randomized controlled trial: Erratum

In the article, "Effects of a 12-week resistance and aerobic exercise program on muscular strength and quality of life in breast cancer survivors: Study protocol for the EFICAN randomized controlled trial",^[1] which appears in Volume 98, Issue 44 of *Medicine*, the table headers for Table 1 were misleading and showed phase 1 extending into week 3. The correct table is:

Week	1	2	3	4	5	6	7	8	9	10	11	12
Session	12	34	56	78	9 10	11 12	13 14	15 16	17 18	19 20	21 22	23 24
Phases	Phase 1: Fa	Phase 2: Circuit Training										
Sets	2	2	2	2	2	3	3	3	3	3	3	2
Repetitions (CE [*] Intensity)	12 (30)	12 (30)	12 (24)	12 (24)	12 (24)	10 (20)	10 (20)	10 (20)	8 (16)	8 (16)	8 (16)	6 (12)
Estimated Intensity (%RM [†])	≅40%	≅40%	≅50%	≅50%	≅50%	≅55%	≅55%	≅55%	≅60%	≅60%	≅60%	≅70%
Total reps per exercise	24	24	24	24	24	30	30	30	24	24	24	12

* CE= Number of repetitions that could the participant could perform with the current weight.

* RM= Repetition Maximum: the weight that can be lifted only once.

Reference

 Soriano-Maldonado A, Carrera-Ruiz A, Díez-Fernández DM. Effects of a 12-week resistance and aerobic exercise program on muscular strength and quality of life in breast cancer survivors: Study protocol for the EFICAN randomized controlled trial. *Medicine*. 98;44:e17625.

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Soriano-Maldonado A, Carrera-Ruiz A, Diez-Fernández DM. Effects of a 12-week resistance and aerobic exercise program on muscular strength and quality of life in breast cancer survivors: Study protocol for the EFICAN randomized controlled trial. Medicine 2019;98:49(e18419). http://dx.doi.org/10.1097/MD.000000000018419